Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease: A Real-World Study

Yael Barer; Olga Sánchez-Soliño; Gabriel Chodick; Meital Grabarnik-John; Shiran Naftelberg Blonder; Neta li Feurestein-Ganor; Lars Bergmann; Connie H. Yan; Sivan Gazit; David Arkadir

doi:10.1007/s12325-024-02924-8

Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease: A Real-World Study

Yael Barer^*, Olga Sánchez-Soliño, Gabriel Chodick, Meital Grabarnik-John, Shiran Naftelberg Blonder, Neta li Feurestein-Ganor, Lars Bergmann, Connie H. Yan, Sivan Gazit, David Arkadir

^*Corresponding author for this work

School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: Early, simple predictors for long-term survival in Parkinson’s disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment. Methods: This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival. Results: Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3–1.7), particularly among patients aged < 75 years (1.8; 1.4–2.4). Conclusion: In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.

Original language	English
Pages (from-to)	3419-3425
Number of pages	7
Journal	Advances in Therapy
Volume	41
Issue number	8
DOIs	https://doi.org/10.1007/s12325-024-02924-8
State	Published - Aug 2024

Funding

Funders	Funder number
AbbVie

Keywords

Antiparkinson’s agents
Drug dosage calculations
Mortality
Parkinson’s disease

Access to Document

10.1007/s12325-024-02924-8

Cite this

Barer, Y., Sánchez-Soliño, O., Chodick, G., Grabarnik-John, M., Blonder, S. N., Feurestein-Ganor, N. L., Bergmann, L., Yan, C. H., Gazit, S., & Arkadir, D. (2024). Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease: A Real-World Study. Advances in Therapy, 41(8), 3419-3425. https://doi.org/10.1007/s12325-024-02924-8

@article{e8beeb26cc5846a68b1543ced22e1a7f,

title = "Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson{\textquoteright}s Disease: A Real-World Study",

abstract = "Introduction: Early, simple predictors for long-term survival in Parkinson{\textquoteright}s disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment. Methods: This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival. Results: Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3–1.7), particularly among patients aged < 75 years (1.8; 1.4–2.4). Conclusion: In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.",

keywords = "Antiparkinson{\textquoteright}s agents, Drug dosage calculations, Mortality, Parkinson{\textquoteright}s disease",

author = "Yael Barer and Olga S{\'a}nchez-Soli{\~n}o and Gabriel Chodick and Meital Grabarnik-John and Blonder, {Shiran Naftelberg} and Feurestein-Ganor, {Neta li} and Lars Bergmann and Yan, {Connie H.} and Sivan Gazit and David Arkadir",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = aug,

doi = "10.1007/s12325-024-02924-8",

language = "אנגלית",

volume = "41",

pages = "3419--3425",

journal = "Advances in Therapy",

issn = "0741-238X",

publisher = "Springer International Publishing AG",

number = "8",

}

Barer, Y, Sánchez-Soliño, O, Chodick, G, Grabarnik-John, M, Blonder, SN, Feurestein-Ganor, NL, Bergmann, L, Yan, CH, Gazit, S & Arkadir, D 2024, 'Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease: A Real-World Study', Advances in Therapy, vol. 41, no. 8, pp. 3419-3425. https://doi.org/10.1007/s12325-024-02924-8

TY - JOUR

T1 - Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease

T2 - A Real-World Study

AU - Barer, Yael

AU - Sánchez-Soliño, Olga

AU - Chodick, Gabriel

AU - Grabarnik-John, Meital

AU - Blonder, Shiran Naftelberg

AU - Feurestein-Ganor, Neta li

AU - Bergmann, Lars

AU - Yan, Connie H.

AU - Gazit, Sivan

AU - Arkadir, David

PY - 2024/8

Y1 - 2024/8

N2 - Introduction: Early, simple predictors for long-term survival in Parkinson’s disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment. Methods: This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival. Results: Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3–1.7), particularly among patients aged < 75 years (1.8; 1.4–2.4). Conclusion: In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.

AB - Introduction: Early, simple predictors for long-term survival in Parkinson’s disease (PD) may help identify patients at elevated risk and are crucial for more personalized treatment. Methods: This large, retrospective study examined whether higher levodopa equivalent daily dose (LEDD) a year after diagnosis predicts long-term survival. Results: Mortality risk was increased among 292 patients receiving ≥ 600 mg LEDD versus 2233 patients receiving < 600 mg LEDD (hazard ratio 1.5; 95% confidence interval 1.3–1.7), particularly among patients aged < 75 years (1.8; 1.4–2.4). Conclusion: In PD, higher LEDD can be an early risk marker of increased mortality, probably because it reflects more severe disease.

KW - Antiparkinson’s agents

KW - Drug dosage calculations

KW - Mortality

KW - Parkinson’s disease

UR - http://www.scopus.com/inward/record.url?scp=85197673954&partnerID=8YFLogxK

U2 - 10.1007/s12325-024-02924-8

DO - 10.1007/s12325-024-02924-8

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 38976124

AN - SCOPUS:85197673954

SN - 0741-238X

VL - 41

SP - 3419

EP - 3425

JO - Advances in Therapy

JF - Advances in Therapy

IS - 8

ER -

Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson’s Disease: A Real-World Study

Abstract

Funding

Keywords

Access to Document

Other files and links

Fingerprint

Cite this